医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

PeptiDream Achieves Milestone for Initiation of Clinical Development for Bristol-Myers Squibb’s First Collaboration Product Candidate

2016年06月15日 PM07:57
このエントリーをはてなブックマークに追加


 

TOKYO

PeptiDream Inc., a public Tokyo-based biopharmaceutical company (“PeptiDream”) (TOKYO:4587) announced today that it has earned a milestone for the dosing of a first patient in a clinical trial by its alliance partner, Bristol-Myers Squibb Company (BMS). This is the first program to enter clinical testing out of the discovery collaboration between the two companies. The molecule being advanced in clinical testing was discovered by Bristol-Myers Squibb starting from an active lead macrocyclic compound identified by Peptidream using its PDPS technology and provided to BMS for further optimization.

Under the terms of the original Discovery and Development Agreement, which was initiated on October 15, 2010 and extended on October 15, 2012, PeptiDream will receive a milestone payment for this event and is eligible to receive additional milestone payments upon the continuation of successful clinical development by BMS. In addition, Peptidream is eligible to receive tiered royalties on net sales of any product that results from the collaboration. Further financial terms have not been disclosed.

Over the past six years, PeptiDream has established funded discovery collaborations with 16 leading pharmaceutical companies; Amgen, AstraZeneca, Bristol-Myers Squibb, Lilly, GlaxoSmithKline, Novartis, Mitsubishi Tanabe, Daiichi Sankyo, Merck, Sanofi, Teijin, Kyorin, Ipsen, Genentech, Shionogi, and Asahi Kasei Pharma all of which are active and ongoing. In addition, PeptiDream has transferred its PDPS discovery platform for broad use to Bristol-Myers-Squibb, Novartis, and Lilly.

[Comment from Kiichi Kubota, President & CEO of PeptiDream Inc]
This is the first macrocyclic peptide to enter clinical testing from the discovery collaboration between the two companies, and represents another validation of the potential of our macrocyclic peptides to offer an exciting alternative to monoclonal antibodies for targeting challenging protein-protein interactions. We have strong hope that product candidates such as these will eventually improve the quality of patients’ lives worldwide.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160615005627/en/

CONTACT

PeptiDream Inc.
Patrick C Reid, +81-3-5790-9991
(TOKYO)
EMAIL: p-reid@peptidream.com
http://www.peptidream.com/

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 印尼生命科学与技术学院在NCRM NICHE 2021上赢得第16届Fujio Cup Quiz大赛;印度Rajalakshmi工程学院获得亚军
  • 辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析
  • ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
  • 硕迪B轮成功融资1亿美元,利用先进的计算和结构药物设计平台加速开发改变患者命运的药物
  • CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease